We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Non2.0
Noni Research
Mostly mechanism / observational
17 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Noni studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality randomised trials published 2004–2026 with a typical study size of 81 participants.
Based on 17 studies · 9 RCTs · 369 total participants
Confidence
Moderate confidence
By outcome
Immune supportNo convincing human evidence for immune benefit; only surrogate antioxidant markers in an industry-funded trial · Unknown / unproven
Too few graded studies1 study
Active research area
8 studies in the last 5 years
200420152026
1Systematic Review2024
In plain English: This review underscores the need for further research into Noni's anticancer properties, with the hope of stimulating additional studies and clinical trials to validate and expand upon these promising findings.
Kitic D, Miladinovic B, Randjelovic M, Szopa A, Seidel V, Prasher P, Sharma M, Fatima R, Arslan Ateşşahin D, Calina D, Sharifi-Rad J. · Phytotherapy research : PTR (2024)
The compiled studies highlight Noni's multifaceted role in cancer therapy, showcasing its various bioactive components and their modes of action.
This includes mechanisms such as apoptosis induction, cell cycle arrest, antiangiogenesis, and immune system modulation, demonstrating significant anticancer and chemopreventive potential.
The findings reinforce Noni's potential as a safe and effective option in cancer prevention and treatment.
In plain English: Confirmation in larger, prospectively registered trials with clinically adjudicated infection-related endpoints is warranted.
Shin SM, Park SH, Bae SG, Park EY, Lee JY, Kwon HY, La IJ, Youn SJ, Choi Y, Choi YE, Kim DH, Park SY, Moon C, Kim TY. · Nutrients (2026)
Adjusted between-group LS mean differences (95% CI) were +8.94 (-0.61, 18.50; p = 0.066) at E:T 50:1, +7.68 (-1.14, 16.50; p = 0.087) at 25:1, and +3.29 (-2.95, 9.54; p = 0.145) at 12.5:1, all favouring treatment but not reaching the conventional threshold for significance in the mITT/FAS.
Prespecified PPS sensitivity analyses reached significance at E:T 50:1 (+11.03; p = 0.025) and 25:1 (+9.94; p = 0.028).
The treatment group also showed greater increases in selected cytokines (IFN-γ, IL-2, IL-6, IL-10) relative to placebo.
In plain English: This review provides an overview of the bioactive components in noni and analyzes the in vitro and in vivo evidence regarding its bioactive compounds and their mechanisms, thus underscoring its potential as a natural intervention targeting multiple pathophysiological mechanisms for the treatment of SMD.
Li CH, Huang YX, Duan Y, Liu GP, Ai ZW, Ai ZF, Li J, Li SX. · Food & function (2025)
Studies indicate that noni and its bioactive components, such as scopoletin, quercetin, rutin, ursolic acid, and polysaccharides, exert beneficial effects on systemic metabolic disorder (SMD).
In plain English: This article stresses the multifaceted neuroprotective effects of noni and reasserts its therapeutic potential against neurodegenerative diseases.
Goel F, Garg VK. · Molecular neurobiology (2025)
Moreover, noni controls cell survival through the PI3K/Akt/mTOR and MAPK pathways, promoting neuronal resistance and anti-apoptosis.
Preclinical evidence is strong in showing the efficacy of noni against neurodegeneration, but clinical evidence is needed to ascertain its translational potential.
However, despite promising preclinical evidence highlighting noni's neuroprotective potential, a significant gap remains in its clinical validation underscoring the need for a comprehensive evaluation of current findings to guide future translational research.
In plain English: Although evidence of its beneficial effects is growing, further clinical studies and standardization of extracts are necessary to ensure its safe and effective use in medical practice.
Among these, antioxidant activity is particularly notable, with different extracts and isolated compounds demonstrating potent free radical scavenging capabilities.
Additionally, the antimicrobial potential against resistant bacteria, healing effects observed in animal models, and immunomodulatory properties further support the traditional therapeutic use of noni.
Moreover, the plant shows promise for applications in the formulation of pharmaceutical, cosmetic, and nutraceutical products.
In plain English: Two patients developed liver injury after noni-juice consumption — one required urgent liver transplantation after sub-acute hepatic failure.
Stadlbauer V, Fickert P, Lackner C, Schmerlaib J, Krisper P, Trauner M, Stauber RE · World J Gastroenterol (2005)
Two-case series of noni-associated hepatotoxicity
A 29-year-old man developed sub-acute hepatic failure after 1.5 L over 3 weeks and required liver transplantation
A 62-year-old woman had self-limited acute hepatitis after 2 L over 3 months
In plain English: A 24-year-old woman developed fulminant hepatitis after 4 weeks of noni juice taken for 'immune stimulation'; liver enzymes normalized after she stopped.
Single case report of fulminant hepatitis temporally linked to noni juice
Viral, metabolic and autoimmune hepatitis were excluded and biopsy indicated drug-induced toxicity, though the patient was concurrently on interferon beta-1a (a competing hepatotoxic exposure), weakening causal attribution to noni
Transaminases normalized within a month of stopping noni juice
In plain English: Noni juice reduced plasma superoxide anion radicals and lipid hydroperoxides in heavy smokers over 30 days — surrogate oxidative-stress markers only, in a manufacturer-conducted trial.
Wang MY, Lutfiyya MN, Weidenbacher-Hoper V, Anderson G, Su CX, West BJ · Chem Cent J (2009)
30-day randomized, double-blind, placebo-controlled trial in 285 heavy smokers
Reduced plasma superoxide anion radicals and lipid hydroperoxides vs placebo
Endpoints were surrogate oxidative-stress markers, not clinical or immune outcomes
In plain English: A manufacturer-conducted study reported no hepatotoxicity of freeze-dried noni puree in HepG2 cells or rats, concluding adverse liver effects are 'unlikely'.
West BJ, Su CX, Jensen CJ · J Toxicol Sci (2009)
In-vitro (HepG2) and subchronic oral toxicity test in Sprague-Dawley rats
No reduction in cell viability and no histopathological liver changes reported
NOAEL for freeze-dried puree reported as >6.86 g/kg